Gastroenterologists will be all too familiar with the difficult decisions that managing inflammatory bowel disease often presents. How aggressively should I treat this patient? Do I expect them to have a mild or aggressive form of disease? Do they need a biologic? If so, which one? And when should I start it? The reality is that the answers that would be right for one patient might be disastrous for another. The growing therapeutic armamentarium will only make these decisions more difficult, and yet, we have seen how other specialties have begun to use the molecular heterogeneity in their diseases to provide some answers. Here, we review the progress that has been made in predicting the future for any given patient with inflammatory bowel disease—whether that is the course of disease that they will experience or whether or not they will respond to, or indeed tolerate, a particular therapy.

中文翻译：

---

我们如何预测患者的病程以及他们是否会对特定治疗产生反应？


胃肠病学家对治疗炎症性肠病经常面临的困难决策非常熟悉。我应该如何积极地治疗该患者？我期望他们患有轻度或侵袭性疾病吗？他们需要生物制品吗？如果有，是哪一个？我应该什么时候开始呢？现实情况是，对一名患者来说正确的答案可能对另一名患者来说是灾难性的。不断增长的治疗手段只会使这些决定变得更加困难，然而，我们已经看到其他专业如何开始利用其疾病中的分子异质性来提供一些答案。在这里，我们回顾了在预测任何特定的炎症性肠病患者的未来方面所取得的进展——无论他们将经历的病程，还是他们是否会对特定疗法做出反应或确实耐受。